Bentiromide

Summary

Bentiromide (CHEMBL1200368) is an approved small-molecule diagnostic agent (ATC V04CK03).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: V04CK03
• Chemistry: 404.4 Da · C23H20N2O5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200368
Name	Bentiromide
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	6957673
ChEBI	CHEBI:31263
ATC	V04CK03
Molecular formula	C23H20N2O5
Molecular weight	404.4
InChIKey	SPPTWHFVYKCNNK-FQEVSTJZSA-N

SMILES: C1=CC=C(C=C1)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)NC3=CC=C(C=C3)C(=O)O

IUPAC name: 4-[[(2S)-2-benzamido-3-(4-hydroxyphenyl)propanoyl]amino]benzoic acid

ChEBI definition: The dipeptide obtained by condensation of N-benzoyl-L-tyrosine with 4-aminobenzoic acid. Used as a noninvasive screening test for exocrine pancreatic insufficiency and to monitor the adequacy of supplemental pancreatic therapy, it is given by mouth: the amount of 4-aminobenzoic acid and its metabolites excreted in the urine is taken as a measure of the chymotrypsin-secreting activity of the pancreas.

Pharmacological roles (ChEBI): diagnostic agent.

Other ChEBI roles (chemical / environmental): indicator, reagent.

Also known as: Bentiromida, Bentiromide, BTPABA PFT, BTPABA, PFT, BTPABA-PFT, BTPABAPFT, Chymex, E-2663, Pfd, BENTIROMIDE, bentiromide

Parent form; salt/anhydrous children: CHEMBL3188891

Patent coverage: 161 distinct patent families (567 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).